Journal of Clinical Oncology, Vol 15, 2858-2865, Copyright © 1997 by American Society of Clinical Oncology

ARTICLES

Immunocytochemical markers in stage I lung cancer: relevance to prognosis

U Pastorino, S Andreola, E Tagliabue, F Pezzella, M Incarbone, G Sozzi, M Buyse, S Menard, M Pierotti and F Rilke
Department of Thoracic Surgery, Royal Brompton Hospital, London, United Kingdom. u.pastorino@rbh.nthames.nhs.uk

PURPOSE: This study investigated the frequency of the expression and prognostic significance of a panel of immunocytochemical markers in resected non-small-cell lung cancer (NSCLC). PATIENTS AND METHODS: A total of 515 cases of pathologic stage I NSCLC were analyzed. The median follow-up time of surviving patients was 102 months. The following immunocytochemical markers were tested: blood group A and precursors of blood antigens; laminin receptor; c-erbB1/epidermal growth factor receptor (EGFR) and c-erbB2/Neu; BCl2; p53; and angiogenesis. Kaplan-Meier estimates of survival and time to recurrence were calculated for clinical variables and biologic markers using the Cox model for multivariate analysis. RESULTS: The pathologic tumor extension (pT) represented the most powerful prognostic factor for survival (P = .0008) and time to recurrence (P = .0007). None of the immunocytochemical markers emerged as an independent predictive factor for survival. Bcl2-positive tumors showed a better time to recurrence (P = .03), but the difference lost statistical significance in the multivariate analysis. Of interest, in the group of 137 patients classified as pT1N0, both EGFR expression and nonangiogenic type of vascular pattern were associated with a poorer survival (P = .02). However, data derived from subset analysis must be interpreted cautiously. CONCLUSION: Our findings do not support a relevant prognostic role of immunocytochemical markers in NSCLC. The evidence is not sufficient to alter clinical practice or even to restrict clinical trials of adjuvant treatments to predefined biologic subsets of patients.

This article has been cited by other articles:

				A. R. Li, D. Chitale, G. J. Riely, W. Pao, V. A. Miller, M. F. Zakowski, V. Rusch, M. G. Kris, and M. Ladanyi EGFR Mutations in Lung Adenocarcinomas: Clinical Testing Experience and Relationship to EGFR Gene Copy Number and Immunohistochemical Expression J. Mol. Diagn., May 1, 2008; 10(3): 242 - 248. [Abstract] [Full Text] [PDF]

				P. Sardari Nia, C. Colpaert, P. Vermeulen, J. Weyler, F. Pezzella, P. Van Schil, and E. Van Marck Different Growth Patterns of Non-Small Cell Lung Cancer Represent Distinct Biologic Subtypes Ann. Thorac. Surg., February 1, 2008; 85(2): 395 - 405. [Abstract] [Full Text] [PDF]

				M. V. Karamouzis, J. R. Grandis, and A. Argiris Therapies Directed Against Epidermal Growth Factor Receptor in Aerodigestive Carcinomas JAMA, July 4, 2007; 298(1): 70 - 82. [Abstract] [Full Text] [PDF]

				B. Dome, J. Timar, J. Dobos, L. Meszaros, E. Raso, S. Paku, I. Kenessey, G. Ostoros, M. Magyar, A. Ladanyi, et al. Identification and clinical significance of circulating endothelial progenitor cells in human non-small cell lung cancer. Cancer Res., July 15, 2006; 66(14): 7341 - 7347. [Abstract] [Full Text] [PDF]

				J. Guo, K. Higashi, Y. Ueda, M. Oguchi, T. Takegami, H. Toga, T. Sakuma, H. Yokota, S. Katsuda, H. Tonami, et al. Microvessel Density: Correlation with 18F-FDG Uptake and Prognostic Impact in Lung Adenocarcinomas J. Nucl. Med., March 1, 2006; 47(3): 419 - 425. [Abstract] [Full Text] [PDF]

				B Sonnweber, M Dlaska, S Skvortsov, S Dirnhofer, T Schmid, and W Hilbe High predictive value of epidermal growth factor receptor phosphorylation but not of EGFRvIII mutation in resected stage I non-small cell lung cancer (NSCLC). J. Clin. Pathol., March 1, 2006; 59(3): 255 - 259. [Abstract] [Full Text] [PDF]

				H Nakamura, N Kawasaki, M Taguchi, and K Kabasawa Survival impact of epidermal growth factor receptor overexpression in patients with non-small cell lung cancer: a meta-analysis Thorax, February 1, 2006; 61(2): 140 - 145. [Abstract] [Full Text] [PDF]

				F. Renyi-Vamos, J. Tovari, J. Fillinger, J. Timar, S. Paku, I. Kenessey, G. Ostoros, L. Agocs, I. Soltesz, and B. Dome Lymphangiogenesis Correlates with Lymph Node Metastasis, Prognosis, and Angiogenic Phenotype in Human Non-Small Cell Lung Cancer Clin. Cancer Res., October 15, 2005; 11(20): 7344 - 7353. [Abstract] [Full Text] [PDF]

				K. Takenaka, S. Ishikawa, K. Yanagihara, R. Miyahara, S. Hasegawa, Y. Otake, Y. Morioka, C. Takahashi, M. Noda, H. Ito, et al. Prognostic Significance of Reversion-Inducing Cysteine-Rich Protein With Kazal Motifs Expression in Resected Pathologic Stage IIIA N2 Non-Small-Cell Lung Cancer Ann. Surg. Oncol., October 1, 2005; 12(10): 817 - 824. [Abstract] [Full Text] [PDF]

				R. P. Regala, C. Weems, L. Jamieson, A. Khoor, E. S. Edell, C. M. Lohse, and A. P. Fields Atypical Protein Kinase C{iota} Is an Oncogene in Human Non-Small Cell Lung Cancer Cancer Res., October 1, 2005; 65(19): 8905 - 8911. [Abstract] [Full Text] [PDF]

				T.-L. Cheng, M.-Y. Chang, S.-Y. Huang, C.-C. Sheu, E.-L. Kao, Y.-J. Cheng, and I.-W. Chong Overexpression of Circulating c-Met Messenger RNA Is Significantly Correlated With Nodal Stage and Early Recurrence in Non-Small Cell Lung Cancer Chest, September 1, 2005; 128(3): 1453 - 1460. [Abstract] [Full Text] [PDF]

				Z. Zheng, G. Bepler, A. Cantor, and E. B. Haura Small Tumor Size and Limited Smoking History Predicts Activated Epidermal Growth Factor Receptor in Early-Stage Non-small Cell Lung Cancer Chest, July 1, 2005; 128(1): 308 - 316. [Abstract] [Full Text] [PDF]

				S. Singhal, A. Vachani, D. Antin-Ozerkis, L. R. Kaiser, and S. M. Albelda Prognostic Implications of Cell Cycle, Apoptosis, and Angiogenesis Biomarkers in Non-Small Cell Lung Cancer: A Review Clin. Cancer Res., June 1, 2005; 11(11): 3974 - 3986. [Abstract] [Full Text] [PDF]

				N. Haruki, K. S. Kawaguchi, S. Eichenberger, P. P. Massion, S. Olson, A. Gonzalez, D. P. Carbone, and T. P. Dang Dominant-Negative Notch3 Receptor Inhibits Mitogen-Activated Protein Kinase Pathway and the Growth of Human Lung Cancers Cancer Res., May 1, 2005; 65(9): 3555 - 3561. [Abstract] [Full Text] [PDF]

				T. Berghmans, A. P. Meert, B. Martin, V. Ninane, and J. P. Sculier Prognostic role of epidermal growth factor receptor in stage III nonsmall cell lung cancer Eur. Respir. J., February 1, 2005; 25(2): 329 - 335. [Abstract] [Full Text] [PDF]

				C. Lu, J.-C. Soria, X. Tang, X.-C. Xu, L. Wang, L. Mao, R. Lotan, B. Kemp, B. N. Bekele, L. Feng, et al. Prognostic Factors in Resected Stage I Non-Small-Cell Lung Cancer: A Multivariate Analysis of Six Molecular Markers J. Clin. Oncol., November 15, 2004; 22(22): 4575 - 4583. [Abstract] [Full Text] [PDF]

				W Hilbe, S Dirnhofer, F Oberwasserlechner, T Schmid, E Gunsilius, G Hilbe, E Woll, and C M Kahler CD133 positive endothelial progenitor cells contribute to the tumour vasculature in non-small cell lung cancer J. Clin. Pathol., September 1, 2004; 57(9): 965 - 969. [Abstract] [Full Text] [PDF]

				F. Tanaka, K. Yanagihara, Y. Otake, Y. Kawano, R. Miyahara, K. Takenaka, H. Katakura, S. Ishikawa, H. Ito, and H. Wada Prognostic Factors in Resected Pathologic (p-) Stage IIIA-N2, Non-Small-Cell Lung Cancer Ann. Surg. Oncol., June 1, 2004; 11(6): 612 - 618. [Abstract] [Full Text] [PDF]

				T C Mineo, V Ambrogi, A Baldi, C Rabitti, P Bollero, B Vincenzi, and G Tonini Prognostic impact of VEGF, CD31, CD34, and CD105 expression and tumour vessel invasion after radical surgery for IB-IIA non-small cell lung cancer J. Clin. Pathol., June 1, 2004; 57(6): 591 - 597. [Abstract] [Full Text] [PDF]

				G. Selvaggi, S. Novello, V. Torri, E. Leonardo, P. De Giuli, P. Borasio, C. Mossetti, F. Ardissone, P. Lausi, and G. V. Scagliotti Epidermal growth factor receptor overexpression correlates with a poor prognosis in completely resected non-small-cell lung cancer Ann. Onc., January 1, 2004; 15(1): 28 - 32. [Abstract] [Full Text] [PDF]

				G. Sozzi, D. Conte, M. Leon, R. Cirincione, L. Roz, C. Ratcliffe, E. Roz, N. Cirenei, M. Bellomi, G. Pelosi, et al. Quantification of Free Circulating DNA As a Diagnostic Marker in Lung Cancer J. Clin. Oncol., November 1, 2003; 21(21): 3902 - 3908. [Abstract] [Full Text] [PDF]

				F. Tanaka, H. Oyanagi, K. Takenaka, S. Ishikawa, K. Yanagihara, R. Miyahara, Y. Kawano, M. Li, Y. Otake, and H. Wada Glomeruloid Microvascular Proliferation Is Superior to Intratumoral Microvessel Density as a Prognostic Marker in Non-Small Cell Lung Cancer Cancer Res., October 15, 2003; 63(20): 6791 - 6794. [Abstract] [Full Text] [PDF]

				F. R. Hirsch, M. Varella-Garcia, P. A. Bunn Jr, M. V. Di Maria, R. Veve, R. M. Bremnes, A. E. Baron, C. Zeng, and W. A. Franklin Epidermal Growth Factor Receptor in Non-Small-Cell Lung Carcinomas: Correlation Between Gene Copy Number and Protein Expression and Impact on Prognosis J. Clin. Oncol., October 15, 2003; 21(20): 3798 - 3807. [Abstract] [Full Text] [PDF]

				W Hilbe, S Dirnhofer, F Oberwasserlechner, W Eisterer, K Ammann, T Schmid, G Hilbe, J Thaler, and E Woll Immunohistochemical typing of non-small cell lung cancer on cryostat sections: correlation with clinical parameters and prognosis J. Clin. Pathol., October 1, 2003; 56(10): 736 - 741. [Abstract] [Full Text] [PDF]

				K M Fong, Y Sekido, A F Gazdar, and J D Minna Lung cancer * 9: Molecular biology of lung cancer: clinical implications Thorax, October 1, 2003; 58(10): 892 - 900. [Abstract] [Full Text] [PDF]

				C. Pellegrini, M. Falleni, A. Marchetti, B. Cassani, M. Miozzo, F. Buttitta, M. Roncalli, G. Coggi, and S. Bosari HER-2/Neu Alterations in Non-Small Cell Lung Cancer: A Comprehensive Evaluation by Real Time Reverse Transcription-PCR, Fluorescence in Situ Hybridization, and Immunohistochemistry Clin. Cancer Res., September 1, 2003; 9(10): 3645 - 3652. [Abstract] [Full Text] [PDF]

				S. Singhal, R. Wiewrodt, L. D. Malden, K. M. Amin, K. Matzie, J. Friedberg, J. C. Kucharczuk, L. A. Litzky, S. W. Johnson, L. R. Kaiser, et al. Gene Expression Profiling of Malignant Mesothelioma Clin. Cancer Res., August 1, 2003; 9(8): 3080 - 3097. [Abstract] [Full Text] [PDF]

				T.-L. Hung, F.-F. Chen, J. M. Liu, W.-W. Lai, A.-L. Hsiao, W.-T. Huang, H. H. W. Chen, and W.-C. Su Clinical Evaluation of HER-2/neu Protein in Malignant Pleural Effusion-Associated Lung Adenocarcinoma and as a Tumor Marker in Pleural Effusion Diagnosis Clin. Cancer Res., July 1, 2003; 9(7): 2605 - 2612. [Abstract] [Full Text] [PDF]

				M. Tomita, Y. Matsuzaki, M. Edagawa, T. Shimizu, M. Hara, and T. Onitsuka Lack of prognostic significance of tumor angiogenesis in resected pN2 non-small cell lung cancer Interactive CardioVascular and Thoracic Surgery, June 1, 2003; 2(2): 201 - 205. [Abstract] [Full Text] [PDF]

				C. Poleri, J. L. Morero, B. Nieva, M. F. Vazquez, C. Rodriguez, E. de Titto, and M. Rosenberg Risk of Recurrence in Patients With Surgically Resected Stage I Non-small Cell Lung Carcinoma: Histopathologic and Immunohistochemical Analysis Chest, June 1, 2003; 123(6): 1858 - 1867. [Abstract] [Full Text] [PDF]

				R. Danesi, F. De Braud, S. Fogli, T. M. De Pas, A. Di Paolo, G. Curigliano, and M. Del Tacca Pharmacogenetics of Anticancer Drug Sensitivity in Non-Small Cell Lung Cancer Pharmacol. Rev., March 1, 2003; 55(1): 57 - 103. [Abstract] [Full Text] [PDF]

				C. Brambilla, F. Fievet, M. Jeanmart, F. de Fraipont, S. Lantuejoul, V. Frappat, G. Ferretti, P.Y. Brichon, and D. Moro-Sibilot Early detection of lung cancer: role of biomarkers Eur. Respir. J., January 1, 2003; 21(39_suppl): 36S - 44s. [Abstract] [Full Text] [PDF]

				A-P. Meert, B. Martin, P. Delmotte, T. Berghmans, J-J. Lafitte, C. Mascaux, M. Paesmans, E. Steels, J-M. Verdebout, and J-P. Sculier The role of EGF-R expression on patient survival in lung cancer: a systematic review with meta-analysis Eur. Respir. J., October 1, 2002; 20(4): 975 - 981. [Abstract] [Full Text] [PDF]

				R.-S. Lai, J.-S. Wang, H.-K. Hsu, H.-C. Chang, C.-H. Lin, and M.-H. Lin Prognostic Evaluation of the Expression of p53 and bcl-2 Oncoproteins in Patients with Surgically Resected Non-small Cell Lung Cancer Jpn. J. Clin. Oncol., October 1, 2002; 32(10): 393 - 397. [Abstract] [Full Text] [PDF]

				H. Joensuu, A. Anttonen, M. Eriksson, R. Makitaro, H. Alfthan, V. Kinnula, and S. Leppa Soluble Syndecan-1 and Serum Basic Fibroblast Growth Factor Are New Prognostic Factors in Lung Cancer Cancer Res., September 15, 2002; 62(18): 5210 - 5217. [Abstract] [Full Text] [PDF]

				A N J Graham, P Maxwell, K Mulholland, A H Patterson, N Anderson, K G McManus, H Bharucha, and J A McGuigan Increased nm23 immunoreactivity is associated with selective inhibition of systemic tumour cell dissemination J. Clin. Pathol., March 1, 2002; 55(3): 184 - 189. [Abstract] [Full Text] [PDF]

				F. Tanaka, Y. Otake, K. Yanagihara, Y. Kawano, R. Miyahara, M. Li, T. Yamada, N. Hanaoka, K. Inui, and H. Wada Evaluation of Angiogenesis in Non-small Cell Lung Cancer: Comparison between Anti-CD34 Antibody and Anti-CD105 Antibody Clin. Cancer Res., November 1, 2001; 7(11): 3410 - 3415. [Abstract] [Full Text] [PDF]

				E. Steels, M. Paesmans, T. Berghmans, F. Branle, F. Lemaitre, C. Mascaux, A.P. Meert, F. Vallot, J.J. Lafitte, and J.P. Sculier Role of p53 as a prognostic factor for survival in lung cancer: a systematic review of the literature with a meta-analysis Eur. Respir. J., October 1, 2001; 18(4): 705 - 719. [Abstract] [Full Text] [PDF]

				J. Brabender, K. D. Danenberg, R. Metzger, P. M. Schneider, J. Park, D. Salonga, A. H. Holscher, and P. V. Danenberg Epidermal Growth Factor Receptor and HER2-neu mRNA Expression in Non-Small Cell Lung Cancer Is Correlated with Survival Clin. Cancer Res., July 1, 2001; 7(7): 1850 - 1855. [Abstract] [Full Text] [PDF]

				F. R. Khuri, H. Wu, J. J. Lee, B. L. Kemp, R. Lotan, S. M. Lippman, L. Feng, W. K. Hong, and X.-C. Xu Cyclooxygenase-2 Overexpression Is a Marker of Poor Prognosis in Stage I Non-Small Cell Lung Cancer Clin. Cancer Res., April 1, 2001; 7(4): 861 - 867. [Abstract] [Full Text]

				A. J. Marrogi, W. D. Travis, J. A. Welsh, M. A. Khan, H. Rahim, H. Tazelaar, P. Pairolero, V. Trastek, J. Jett, N. E. Caporaso, et al. Nitric Oxide Synthase, Cyclooxygenase 2, and Vascular Endothelial Growth Factor in the Angiogenesis of Non-Small Cell Lung Carcinoma Clin. Cancer Res., December 1, 2000; 6(12): 4739 - 4744. [Abstract] [Full Text]

				T. Mitsudomi, N. Hamajima, M. Ogawa, and T. Takahashi Prognostic Significance of p53 Alterations in Patients with Non-Small Cell Lung Cancer: A Meta-Analysis Clin. Cancer Res., October 1, 2000; 6(10): 4055 - 4063. [Abstract] [Full Text]

				X. Tang, F. R. Khuri, J. J. Lee, B. L. Kemp, D. Liu, W. K. Hong, and L. Mao Hypermethylation of the Death-Associated Protein (DAP) Kinase Promoter and Aggressiveness in Stage I Non-Small-Cell Lung Cancer J Natl Cancer Inst, September 20, 2000; 92(18): 1511 - 1516. [Abstract] [Full Text] [PDF]

				F. R. Khuri, R. Lotan, B. L. Kemp, S. M. Lippman, H. Wu, L. Feng, J. J. Lee, C. S. Cooksley, B. Parr, E. Chang, et al. Retinoic Acid Receptor-Beta as a Prognostic Indicator in Stage I Non-Small-Cell Lung Cancer J. Clin. Oncol., August 15, 2000; 18(15): 2798 - 2804. [Abstract] [Full Text] [PDF]

				G. Ferretti, G. Curigliano, U. Pastorino, A. Cittadini, G. Flamini, M. G. Calabrò, Tommaso De Pas, L. Orlando, M. Mandalà, M. Colleoni, et al. Detection by Denaturant Gradient Gel Electrophoresis of Tumor-specific Mutations in Biopsies and Relative Bronchoalveolar Lavage Fluid from Resectable Non-Small Cell Lung Cancer Clin. Cancer Res., June 1, 2000; 6(6): 2393 - 2400. [Abstract] [Full Text]

				T. A. D’Amico, T. A. Aloia, M.-B. H. Moore, J. E. Herndon II, K. R. Brooks, C. L. Lau, and D. H. Harpole Jr Molecular biologic substaging of stage I lung cancer according to gender and histology Ann. Thorac. Surg., March 1, 2000; 69(3): 882 - 886. [Abstract] [Full Text] [PDF]

				R. S. Herbst, S. Yano, H. Kuniyasu, F. R. Khuri, C. D. Bucana, F. Guo, D. Liu, B. Kemp, J. J. Lee, W. K. Hong, et al. Differential Expression of E-cadherin and Type IV Collagenase Genes Predicts Outcome in Patients with Stage I Non-Small Cell Lung Carcinoma Clin. Cancer Res., March 1, 2000; 6(3): 790 - 797. [Abstract] [Full Text]

				I. Murakami, K. Hiyama, S. Ishioka, M. Yamakido, F. Kasagi, and Y. Yokosaki p53 Gene Mutations Are Associated with Shortened Survival in Patients with Advanced Non-small Cell Lung Cancer: An Analysis of Medically Managed Patients Clin. Cancer Res., February 1, 2000; 6(2): 526 - 530. [Abstract] [Full Text]

				T. Mishina, H. Dosaka-Akita, F. Hommura, M. Nishi, T. Kojima, S. Ogura, M. Shimizu, H. Katoh, and Y. Kawakami Cyclin E Expression, a Potential Prognostic Marker for Non-Small Cell Lung Cancers Clin. Cancer Res., January 1, 2000; 6(1): 11 - 16. [Abstract] [Full Text]

				K. M. Fong, Y. Sekido, and J. D. Minna MOLECULAR PATHOGENESIS OF LUNG CANCER J. Thorac. Cardiovasc. Surg., December 1, 1999; 118(6): 1136 - 1152. [Abstract] [Full Text] [PDF]

				T. Hashimoto, Y. Tokuchi, M. Hayashi, Y. Kobayashi, K. Nishida, S.-i. Hayashi, Y. Ishikawa, S. Tsuchiya, K. Nakagawa, J.-i. Hayashi, et al. p53 Null Mutations Undetected by Immunohistochemical Staining Predict a Poor Outcome with Early-Stage Non-Small Cell Lung Carcinomas Cancer Res., November 1, 1999; 59(21): 5572 - 5577. [Abstract] [Full Text] [PDF]

				G. Sozzi, K. Musso, C. Ratcliffe, P. Goldstraw, M. A. Pierotti, and U. Pastorino Detection of Microsatellite Alterations in Plasma DNA of Non-Small Cell Lung Cancer Patients: A Prospect for Early Diagnosis Clin. Cancer Res., October 1, 1999; 5(10): 2689 - 2692. [Abstract] [Full Text] [PDF]

				J. Mattern, R. Koomagi, and M. Volm Biological Characterization of Subgroups of Squamous Cell Lung Carcinomas Clin. Cancer Res., June 1, 1999; 5(6): 1459 - 1463. [Abstract] [Full Text] [PDF]